Form 4: Arcutis CMO Patrick Burnett Sells Shares for Tax Coverage

Arcutis Biotherapeutics EVP and Chief Medical Officer Patrick Burnett sold 684 shares to satisfy tax withholding obligations.

Summary

• Patrick Burnett, EVP and Chief Medical Officer of Arcutis Biotherapeutics, sold 684 shares of common stock on May 4, 2026.
• The shares were sold at a weighted average price of $23.6106 per share.
• The transaction was executed to cover tax withholding obligations related to the vesting of Restricted Stock Units.
• Following the transaction, the reporting person retains beneficial ownership of 120,466 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely for tax compliance purposes and does not reflect a change in the executive's outlook on the company.

Positives

• The sale was non-discretionary, executed solely to satisfy tax obligations associated with equity vesting.

Negatives

• Reduction in direct equity holdings by a key executive.

Risks

• Market volatility affecting the value of remaining equity holdings.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

Industry Context

StockSavvy.ai notes that this is a routine administrative filing common in the biotechnology sector, where equity-based compensation is a standard component of executive remuneration packages.

Comparison to Industry Standards

• The transaction aligns with standard industry practices for managing tax liabilities arising from RSU vesting events.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine tax-related sell-to-cover event.

Next Steps

• None mentioned.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Insider Trading, Form 4, Biotech, Executive Compensation